Theravance wins $20M milestone on FDA approval

Theravance has earned a $20 million milestone payment from partner Astellas Pharma. The FDA's approval of Vibativ (telavancin) triggered the payment. Release

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.